Literature DB >> 6333937

Ellagic acid: a potent naturally occurring inhibitor of benzo[a]pyrene metabolism and its subsequent glucuronidation, sulfation and covalent binding to DNA in cultured BALB/C mouse keratinocytes.

H Mukhtar, B J Del Tito, C L Marcelo, M Das, D R Bickers.   

Abstract

The metabolism of [3H]benzo[a]pyrene (BP) by cultured primary keratinocytes prepared from BALB/C mouse epidermis was found to be largely inhibited by the dietary plant phenol, ellagic acid. Varying concentrations of ellagic acid added to the keratinocyte cultures resulted in a dose-dependent inhibition of the cytochrome P-450-dependent monooxygenases aryl hydrocarbon hydroxylase (AHH) and 7-ethoxycoumarin-O-deethylase (ECD). The major organic solvent-extractable metabolites found intracellularly in the cultured cells were trans-7,8-dihydro-7,8-dihydroxybenzo[a]-pyrene (BP-7,8-diol) and 3-hydroxybenzo[a]pyrene (3-OH-BP), although small amounts of 9-hydroxybenzo[a]pyrene, quinones and trans-9,10-dihydro-9,10-dihydroxybenzo[a]-pyrene (BP-9,10-diol) were also present. The major organic solvent-extractable metabolites found in the extracellular culture medium were BP-7,8-diol and BP-9,10-diol, with smaller quantities of unconjugated phenols and quinones. The major intracellular and extracellular water-soluble metabolites of BP were conjugated with glucuronide (primarily 3-OH-BP and several BP-quinones), and to a lesser extent with sulfate (primarily BP-7,8-diol). Both intracellular and extracellular metabolism of organic solvent-extractable and water-soluble conjugates was significantly inhibited by ellagic acid in a dose-dependent manner. The intracellular enzyme-mediated binding of BP to mouse keratinocyte DNA was also largely inhibited in a dose-dependent fashion by ellagic acid. Our results indicate that cultured primary mouse keratinocytes offer a useful model system for studying factors affecting the metabolic activation and detoxification of polycyclic aromatic hydrocarbon carcinogens in the epidermis, and that polyphenolic compounds such as ellagic acid may prove useful in modulating the risk of cutaneous cancer that results from exposure to these environmental chemicals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333937     DOI: 10.1093/carcin/5.12.1565

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

Review 1.  The use of cultured epithelial and endothelial cells for drug transport and metabolism studies.

Authors:  K L Audus; R L Bartel; I J Hidalgo; R T Borchardt
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 2.  Tannins, xenobiotic metabolism and cancer chemoprevention in experimental animals.

Authors:  C Nepka; E Asprodini; D Kouretas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.569

3.  Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats.

Authors:  T Tanaka; H Iwata; K Niwa; Y Mori; H Mori
Journal:  Jpn J Cancer Res       Date:  1988-12

Review 4.  Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Carla Marina Salgado Castillo; Rodrigo Caroca; Marco A Lazo-Vélez; Halyna Antonyak; Alexandr Polishchuk; Roman Lysiuk; Petro Oliinyk; Luigi De Masi; Paola Bontempo; Miquel Martorell; Sevgi Durna Daştan; Daniela Rigano; Michael Wink; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-02-21       Impact factor: 6.543

5.  Metabolic activation of benzo(a)pyrene in SENCAR and BALB/c mouse embryo cell cultures.

Authors:  W M Baird; S M Sebti; L A Reinsvold
Journal:  Environ Health Perspect       Date:  1986-09       Impact factor: 9.031

6.  A comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat.

Authors:  Gurbet Celik; Aslı Semiz; Serdar Karakurt; Sevki Arslan; Orhan Adali; Alaattin Sen
Journal:  Biomed Res Int       Date:  2013-07-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.